EBA Unit
This unit was established in 2008 and conducts early bactericidal studies on new tuberculosis drugs drugs. Prior studies on bedaquiline, Pretomanid and delamanid have resulted in these drugs being registered for short course MDR TB treatment were conducted in this unit. Participants can be admitted in this state-of-the-art laminar flow facility where intensive pk testing is conducted. The unit has been used for vaccination studies, COVID-19 studies as well as complex PK studies for tuberculosis drug development.